Dataset Information

An international multidisciplinary consensus statement on MAFLD and the risk of CVD.

ABSTRACT:

Background

Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of ~ 25-30% and is also associated with cardiovascular disease (CVD). Since systemic metabolic dysfunction underlies its pathogenesis, the term metabolic (dysfunction)-associated fatty liver disease (MAFLD) has been proposed for this condition. MAFLD is closely intertwined with obesity, type 2 diabetes mellitus and atherogenic dyslipidemia, which are established cardiovascular risk factors. Unlike CVD, which has received attention in the literature on fatty liver disease, the CVD risk associated with MAFLD is often underestimated, especially among Cardiologists.

Methods and results

A multidisciplinary panel of fifty-two international experts comprising Hepatologists, Endocrinologists, Diabetologists, Cardiologists and Family Physicians from six continents (Asia, Europe, North America, South America, Africa and Oceania) participated in a formal Delphi survey and developed consensus statements on the association between MAFLD and the risk of CVD. Statements were developed on different aspects of CVD risk, ranging from epidemiology to mechanisms, screening, and management.

Conculsions

The expert panel identified important clinical associations between MAFLD and the risk of CVD that could serve to increase awareness of the adverse metabolic and cardiovascular outcomes of MAFLD. Finally, the expert panel also suggests potential areas for future research.

SUBMITTER: Zhou XD

PROVIDER: S-EPMC10198034 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

An international multidisciplinary consensus statement on MAFLD and the risk of CVD.

Zhou Xiao-Dong XD Targher Giovanni G Byrne Christopher D CD Somers Virend V Kim Seung Up SU Chahal C Anwar A CAA Wong Vincent Wai-Sun VW Cai Jingjing J Shapiro Michael D MD Eslam Mohammed M Steg Philippe Gabriel PG Sung Ki-Chul KC Misra Anoop A Li Jian-Jun JJ Brotons Carlos C Huang Yuli Y Papatheodoridis George V GV Sun Aijun A Yilmaz Yusuf Y Chan Wah Kheong WK Huang Hui H Méndez-Sánchez Nahum N Alqahtani Saleh A SA Cortez-Pinto Helena H Lip Gregory Y H GYH de Knegt Robert J RJ Ocama Ponsiano P Romero-Gomez Manuel M Fudim Marat M Sebastiani Giada G Son Jang Won JW Ryan John D JD Ikonomidis Ignatios I Treeprasertsuk Sombat S Pastori Daniele D Lupsor-Platon Monica M Tilg Herbert H Ghazinyan Hasmik H Boursier Jerome J Hamaguchi Masahide M Nguyen Mindie H MH Fan Jian-Gao JG Goh George Boon-Bee GB Al Mahtab Mamun M Hamid Saeed S Perera Nilanka N George Jacob J George Jacob J Zheng Ming-Hua MH

Hepatology international 20230519 4

<h4>Background</h4>Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of ~ 25-30% and is also associated with cardiovascular disease (CVD). Since systemic metabolic dysfunction underlies its pathogenesis, the term metabolic (dysfunction)-associated fatty liver disease (MAFLD) has been proposed for this condition. MAFLD is closely intertwined with obesity, type 2 diabetes mellitus and atherogenic dyslipidemia, which are ...[more]

PMID: 37204656

Similar Datasets

Project description:The multidisciplinary International Committee for the Advancement of Procedural Sedation presents the first fasting and aspiration prevention recommendations specific to procedural sedation, based on an extensive review of the literature. These were developed using Delphi methodology and assessment of the robustness of the available evidence. The literature evidence is clear that fasting, as currently practiced, often substantially exceeds recommended time thresholds and has known adverse consequences, for example, irritability, dehydration and hypoglycaemia. Fasting does not guarantee an empty stomach, and there is no observed association between aspiration and compliance with common fasting guidelines. The probability of clinically important aspiration during procedural sedation is negligible. In the post-1984 literature there are no published reports of aspiration-associated mortality in children, no reports of death in healthy adults (ASA physical status 1 or 2) and just nine reported deaths in adults of ASA physical status 3 or above. Current concerns about aspiration are out of proportion to the actual risk. Given the lower observed frequency of aspiration and mortality than during general anaesthesia, and the theoretical basis for assuming a lesser risk, fasting strategies in procedural sedation can reasonably be less restrictive. We present a consensus-derived algorithm in which each patient is first risk-stratified during their pre-sedation assessment, using evidence-based factors relating to patient characteristics, comorbidities, the nature of the procedure and the nature of the anticipated sedation technique. Graded fasting precautions for liquids and solids are then recommended for elective procedures based upon this categorisation of negligible, mild or moderate aspiration risk. This consensus statement can serve as a resource to practitioners and policymakers who perform and oversee procedural sedation in patients of all ages, worldwide.

Dataset Information

An international multidisciplinary consensus statement on MAFLD and the risk of CVD.

Background

Methods and results

Conculsions

Publications

An international multidisciplinary consensus statement on MAFLD and the risk of CVD.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets